Video

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Author(s):

Amir Fathi, MD, Massachusetts General Hospital

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Related Videos
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Related Content
LBS-007 receives fast track status from the FDA for use in patients with acute myeloid leukemia.
December 3rd 2024

FDA Awards Fast Track Designation to LBS-007 for Acute Myeloid Leukemia

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Neil P. Shah, MD, PhD
December 1st 2024

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24